Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04470622 · ClinicalTrials.gov registry record · Phase 2
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
A Phase 2 study, sponsored by Heron Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT04470622 is a Phase 2 study that was terminated before completion, run by Heron Therapeutics. The registered enrollment target is 27 participants.
The verdict
NCT04470622, a Phase 2 study, was terminated before completion, sponsored by Heron Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy and safety of aprepitant injectable emulsion added to standard of care for hospitalized patients with COVID-19.
Interventions
- DRUG Saline Placebo
- DRUG Aprepitant injectable emulsion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-07-20 |
| Est. Completion | 2021-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04470622
The ClinicalTrials.gov registry entry for NCT04470622 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heron Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline Placebo is the first listed.
NCT04470622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04470622 about?
NCT04470622 is a clinical study titled "Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)". The study will evaluate the efficacy and safety of aprepitant injectable emulsion added to standard of care for hospitalized patients with COVID-19.
What is the current status of trial NCT04470622?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2020-07-20. Estimated completion is 2021-06-03.
What interventions are being tested in trial NCT04470622?
The interventions under investigation include: Saline Placebo (DRUG), Aprepitant injectable emulsion (DRUG).
Who is sponsoring clinical trial NCT04470622?
This trial is sponsored by Heron Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.